See the DrugPatentWatch profile for dovato
Dovato, a combination HIV medication, is manufactured by ViiV Healthcare [1]. ViiV Healthcare is a global specialist HIV company established in 2009 by GlaxoSmithKline (GSK) and Pfizer, with Shionogi later joining in 2012 [1][2].
Who makes Dovato?
Dovato is produced by ViiV Healthcare, a company dedicated to advancing HIV treatment and prevention [1][2].
What is Dovato used for?
Dovato is a complete, single-tablet regimen used to treat HIV-1 infection in adults and adolescents 12 years of age and older who weigh at least 35 kg [3]. It is prescribed for individuals who have no known or suspected resistance to either of its active ingredients, dolutegravir or lamivudine [3].
How does Dovato work?
Dovato contains two antiretroviral medicines: dolutegravir and lamivudine [3]. Dolutegravir is an integrase strand transfer inhibitor (INSTI) that blocks the HIV integrase enzyme, preventing the virus from integrating its genetic material into the DNA of host cells [3]. Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that works by interfering with an enzyme HIV needs to copy itself, thereby reducing the amount of HIV in the body [3]. Together, these components help lower the viral load in the body [3].
When will Dovato patents expire?
Patent expiry dates for medications are subject to change due to factors like patent challenges and new filings. Information on specific patent expirations for Dovato can be tracked on resources such as DrugPatentWatch.com [4]. These timelines are crucial for understanding when generic versions of the drug might become available.
What are the alternatives to Dovato?
Other treatment options for HIV exist, including different single-tablet regimens and multi-pill regimens containing various classes of antiretroviral drugs [5]. The choice of HIV medication depends on individual patient factors, including viral resistance, comorbidities, and potential drug interactions [5].
What are the side effects of Dovato?
Common side effects reported with Dovato include insomnia, headache, diarrhea, nausea, and fatigue [3]. More serious side effects, though less common, can include hypersensitivity reactions, liver problems, and lactic acidosis [3]. Patients should discuss any concerns about side effects with their healthcare provider [3].
Can I switch to Dovato from another HIV medication?
Switching to Dovato from another HIV medication is a decision made in consultation with a healthcare provider [3]. This decision is typically based on an individual's current viral load, resistance profile, and overall health status [3].
Where can I find more information on HIV treatments?
Reliable sources for information on HIV treatments include government health organizations, reputable medical institutions, and patient advocacy groups [5][6]. DrugPatentWatch.com provides specific data related to drug patents and market exclusivity [4].
Sources:
[1] https://www.viivhealthcare.com/
[2] https://www.viivhealthcare.com/about-viiv-healthcare/
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212173s000lbl.pdf
[4] https://drugpatentwatch.com/
[5] https://www.aids.gov/hiv-aids-basics/staying-healthy-with-hiv/hiv-treatment/
[6] https://www.hiv.gov/hiv-basics/staying-healthy-with-hiv/hiv-treatment/hiv-treatment-overview